The supplement industry is abuzz with talk of the New Dietary Ingredient guidance the FDA released in August.
If fully enforced, impact on the supplement market could be calamitous, but with the comment period extended into December and the FDA largely stone-faced on the finality of the current version, nobody in the industry has a complete view of how the developments will play out.
We gathered six industry figures at Natural Products Expo East and asked them for their quick perspectives.
Get the insider's view from supplements lawyer Ivan Wasserman, Twinlab CEO Naomi Whittel, Will Rowe from Nutrasource, NBJ founder Tom Aarts , NOW Foods CEO Jim Emme and Scott Steinford, executive director of the CoQ10 Association. That’s six voices in seven minutes for the quick take on what could be the biggest regulatory challenge for supplement makers since the passage of DSHEA.
More voices will weigh in on Nov. 16 during the NBJ webinar "The New NDI Guidance, Impact on Industry and Investment." Join William Hood, managing director of Houlihan Lokey; Wellvest Capital Managing Director David Thibodeau; Skye Lininger of Healthnotes; and Jason Sapsin, counsel at Faegre Baker Daniels LLP for a primer on the guidance and its potential effects, followed by a lively Q&A. Register here.
About the Author(s)
You May Also Like